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Abstract
Background:
The combination of telemedicine systems integrating mobile technologies with the use of continuous glucose 
monitors improves patients’ glycemic control but demands a higher interaction with information technology 
tools that must be assessed. In this article, we analyze patients’ behavior from the use-of-the-system point 
of view, identifying how continuous monitoring may change the interaction of patients with the mobile 
telemedicine system.
Methods:
Patients’ behavior were evaluated in a clinical experiment consisting of a 2-month crossover randomized study 
with 10 type 1 diabetes patients. During the entire experiment, patients used the DIABTel telemedicine system, 
and during the intervention phase, they wore a continuous glucose monitor. Throughout the experiment, 
all user actions were automatically registered. This article analyzes the occurrence of events and the behavior 
patterns in blood glucose (BG) self-monitoring and insulin adjustments. A subjective evaluation was also performed 
based on the answers of the patients to a questionnaire delivered at the end of the study.
Results:
The number of sessions established with the mobile Smart Assistant was considerably higher during the 
intervention period than in the control period (29.0 versus 18.8, p < .05), and it was also higher than the number 
of Web sessions (29.0 versus 22.2, p < .01). The number of daily boluses was higher during the intervention 
period than in the control period (5.27 versus 4.40, p < .01). The number of daily BG measurements was 
also higher during the intervention period (4.68 versus 4.05, p < .05) and, in percentage, patients increased 
the BG measurements not associated to meals while decreasing the percentage of preprandial measurements. 
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Introduction
Due to its multifactorial and systemic character, 
diabetes mellitus is considered a paradigm of chronic 
disorders, which has led to an extensive application of 
information technologies in diabetes care.1 Thus diabetes 
has been a major focus of biomedical engineering efforts. 
These efforts are promoted by the recommendations 
given by the World Health Organization in a 2002 report,2 
which presents a number of actions to improve the 
treatment of chronic patients through a change in the 
paradigm of patient’s care. This change must be followed 
by an extended and better use of information and 
communication technologies (ICT) in chronic patients’ care.
Telemedicine has shown a positive influence on diabetes 
care, providing innovative solutions for the diagnosis, 
monitoring, and treatment of diabetes patients,3 but there 
are some problems that delay the widespread implement-
ation of telemedicine systems and place telemedicine 
between fading and future.4 Earlier experiences aimed to 
facilitate remote monitoring of patients from home by the 
transmission of computerized blood glucose (BG) profiles 
to the hospital.5–7 Technology evolution has enabled the 
development of advanced systems based on more powerful 
and easy-to-use terminals and applications, including 
Web-based systems, in particular.8,9 Some telemedicine 
systems for diabetes patients use a distributed approxi-
mation, where patients can download data that are sent 
to the hospital and can be accessed by doctors, enhancing 
physician–patient interaction.8,10,11
The rapid growth and development of mobile computing 
and mobile Internet is changing the way people access 
common services and is revolutionizing telemedicine and 
shared care services, providing independence, mobility, 
and ubiquity to the patients, extending the features 
of conventional telemedicine systems. The mobility and 
freedom provided by mobile technologies allows improving 
patients’ care in an ambulatory scenario.12
Some of the latest telemedicine systems in diabetes include 
manual sending of BG levels by handheld devices, which 
motivates self-care management of diabetes.13,14 Others 
are focused on manual transmission of BG results and 
real-time expert feedback by mobile phone,15 providing 
an added value that can only be reached by introducing 
mobile technologies. The natural next step is to include 
automatic data downloading from medical devices and to 
transfer the downloaded data to physicians, maintaining 
expert feedback.16,17
A modern mobile telemedicine system for diabetes care in 
ambulatory scenarios should facilitate the patient’s efforts 
to collect monitoring data and provide communication 
capabilities with a patient’s personal devices. A mobile-
phone-based health management platform should auto- 
matically capture biological and physiological information. 
These health-related data must be analyzed, treated, and 
stored. The timely “personal health information” can 
be processed locally in the device, to be transferred 
immediately to a network-connected server for further 
processing and/or to be displayed for human analysis, 
and stored for later retrieval and analysis.18
The growing availability of continuous data coming 
from glucose sensors and subcutaneous insulin infusion 
pumps allows patients and physicians to make better 
Abstract cont.
Conclusions:
The use of a continuous glucose monitor changes the way patients manage their diabetes, as observed in the 
increased number of daily insulin bolus, the increased number of daily BG measurements, and the differences 
in the distribution of BG measurements throughout the day. Continuous monitoring also increases the interaction 
of patients with the information system and modifies their patterns of use. We can conclude that mobile 
technologies are especially useful in scenarios of tight monitoring in diabetes, and they are well accepted 
by patients.
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therapeutic decisions but supposes a huge quantity of 
data that are difficult to manage using mobile terminals. 
Therefore, it is crucial to define new ICT architectures for 
efficient management of data storage, data transmission, 
and data visualization in the context of continuous 
monitoring.19
In previous studies, we observed that combining our tele- 
medicine system with continuous monitoring improves 
patients’ glycemic control and modifies self-management 
of insulin treatment.20,21 In this article, we analyze patients’ 
behavior from the use-of-the-system perspective 
throughout a 2-month clinical experiment, identifying 
how continuous monitoring changes the interaction of 
patients with the mobile telemedicine system.
Methods
Clinical Experiment
The clinical experiment consisted of a 2-month crossover 
randomized study, each phase lasting 4 weeks, with 
an interim wash-out period of 6 weeks.20 Ten type 1 
patients [5 women, 41.2 (range, 21–62) years old, duration 
of diabetes 14.9 (range, 3–52) years] were included, and 
they used the DIABTel system,22–24 which supported the 
interactions between doctors and patients.
In both experimental phases, patients used a personal 
assistant, called Smart Assistant (SA),21 running on a 
personal digital assistant (PDA), which provides patients 
with flexible tools for data visualization, management 
of his/her monitoring data, and downloading of data 
from an insulin pump (D-tron plus, Disetronic, Burgdorf, 
Switzerland), via Infrared Data Association or BluetoothTM. 
The SA application is able to manage a local database, 
allowing the patient to work isolated from the telemedicine 
system. Self-monitoring of BG data were measured 
with the Roche Accutrend® glucose meter (Boehringer 
Mannheim, Mannheim, Germany) and were transmitted 
through a conventional phone line using the Roche 
Acculink® modem (Roche Diagnostics, Basel, Switzerland). 
After transmission, BG data were immediately available 
on the Web. During both experimental phases, patients 
used the SA whenever they had to communicate with 
the insulin pump. On patient’s demand, the SA application 
communicates with the DIABTel server and automatically 
updates all the new information in both directions. 
In the 24 h period following data reception, doctors 
analyzed patients’ data and advised treatment changes as 
necessary. Patients received instruction to synchronize the 
SA at least once a week without any specific guideline 
about the Web or SA functionalities they should use.
During the control phase, patients used the DIABTel 
system. During the intervention phase, patients also 
wore a continuous glucose monitoring (CGM) device 
(Guardian® RT, Continuous Glucose Monitoring System, 
Medtronic MiniMed, Northdridge, CA) 3 days per week. 
Patients had real-time information of their BG levels; 
however, the CGM data were retrospectively analyzed. 
While wearing the CGM device, patients were not expressly 
asked to perform a predefined number of finger-prick 
tests apart from the two a day required for calibration. 
Figure 1 shows an overview of the devices and applications 
the patients used during the clinical experimental phases.
System Evaluation
The system was evaluated from an objective point of 
view with the automatic tracking of a user’s interactions 
with the PDA or the Web to obtain information about the 
use of the system. Additionally, a subjective evaluation 
was made based on a questionnaire fulfilled online 
by patients at the end of the experiment, where they 
reflected their impressions about the system and especially 
about the SA application. This questionnaire was specifically 
created for the experiment, and among others, it asks 
whether the PDA and the SA are easy to use, whether 
patients think that the SA is secure and keeps their 
intimacy, whether it helps patients with their daily diabetes 
self-management, whether it reduces the number and 
level of incidences and whether it helps solving or 
avoiding them, and whether they would recommend the 
use of the system to other patients.
The questionnaire includes a section about the utility 
of the CGM device, where patients were asked if CGM 
makes them more confident with their decisions regarding 
diabetes, if it helps preventing problematic situations, and 
if it provides them with more freedom.
Objective evaluation was made studying the user-
interaction events that were automatically registered 
in DIABTel’s database during the experiment. For each 
event, data related to the patient’s identification, the type 
of action, and the date and time of the generation of the 
event is registered. This information allows the study 
of patients’ behavior patterns of use of the system at 
each experimental phase.
The events registered are start session, finish session, 
database synchronization, data downloaded from the insulin 
pump, read serial number, new treatment notification, 
logbook visualization, insert glucose data, insert diet data, 
insert additional data, modify additional data, graphics 
visualization, pump therapy visualization, and diet therapy 
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visualization. These actions can be performed by the 
patient using the SA or using other applications of 
the system like the Web application, accepting data 
downloading from the insulin pump, reading the serial 
number, or database synchronization that can only be 
carried out with the SA.
For each experimental phase, we computed the number 
of sessions established in the SA application and the 
functionalities of the system used by the patients. To asses 
the impact of CGM in patients’ behavior, we analyzed 
the changes in the number of boluses carried out by the 
patients and also the number of capillary BG measurements 
and the time of these measurements. We aimed to discover 
if the number of changes in the insulin regime, and 
measurements are higher during the intervention period 
than in the control period.
We finished the analysis by comparing the number of 
sessions registered at the SA application versus the 
number of Web sessions for each period. Our intention 
was to check if patients used the SA functionalities that 
Figure 1. Overall architectural overview of the system. PSTN, public switched telephone network; IrDA, Infrared Data Association; DB, database; 
GPRS, general packet radio service.
are also available in the Web application, with which 
patients could be more familiar.
Results
Objective Evaluation of the Smart Assistant
Figure 2 shows the number of sessions in the SA for 
the intervention and control periods. We can observe 
that the number of sessions during the intervention 
period is considerably higher than in the control period 
(29.0 versus 18.8, p < .05). Figure 3 shows the total time 
of SA usage for each experimental phase. The total time 
spent by patients with the system was greater during 
the intervention phase (04:27:11 versus 01:47:07, p < .01). 
If we analyze the average duration of each session, 
there is no statistically significant difference between the 
two periods.
In Figure 4, shows the use of the functionalities of the 
SA weighted by the number of sessions. We detected that, 
during the control phase, patients used the functionalities 
related to “logbook visualization,” “data downloaded 
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from the insulin pump,” or “read serial number” events 
more times per session. The functionalities “insulin pump 
therapy visualization” and “diet therapy visualization” 
were employed more often during the intervention phase. 
The “insulin pump therapy visualization” was used 
significantly more during the intervention phase (p < .05) 
than in control phase, and “graphics visualization” was 
only generated during the intervention phase.
Figure 2. Number of SA sessions per period.
Figure 3. Total time of SA use per period.
Figure 4. Use of the SA functionalities per period weighted by the 
number of sessions.
The average number of daily BG measurements and the 
number of daily boluses can be seen in Figures 5 and 6. 
During the intervention phase, the number of boluses 
has higher than in the control period (5.27 versus 4.40, 
p < .01), and the same happens for the number of BG 
measurements (4.68 versus 4.05, p < .05).
Figure 7 shows the distribution of BG measurements in 
moments of the day. The number of measurements not 
associated to meals was higher during the intervention 
phase than in the control phase.
Figure 8 shows a comparison between the number of 
sessions established by the patients in the Web application 
and the SA for each period. The number of SA sessions 
during the intervention phase was higher than the number 
of Web sessions (29.0 versus 22.2, p < .01). There was no 
statistical significance when comparing the number of 
sessions between Web and SA during the control phase.
Subjective Evaluation of the Smart Assistant
Regarding the results obtained with the questionnaire, 
in the section related to the technical validation and 
utility of the SA (easy to use and to learn, utility in 
downloading data from the insulin pump and later 
Figure 5. Average number of daily boluses per period.
Figure 6. Average number of daily BG measurements per period.
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visualization, respects my intimacy), the system obtained 
150 points out of 162. The aspects related to global 
usability were pointed positively, obtaining 134 points 
out of 144. Among the aspects asked in this global 
usability section, we can highlight that 87.5% of the 
patients disagree with the statement that “the system has 
made my daily life harder.”
Related to the utility of the DIABTel system (impact in 
the communication with the doctor, number and level of 
incidences, the system helps me taking decisions, makes 
me feel safer in my diabetes self-management), the score 
was 133 points out of 141. All patients would recommend 
the use of the DIABTel system for diabetes care.
The answers regarding the utility of CGM show that 80% 
of the patients agree or partially agree with the statement 
that the use of a CGM makes them more confident about 
diabetes, 60% think that CGM helps them preventing 
problematic situations, and 80% believe that the CGM 
provides them with more freedom.
Figure 7. Distribution of BG measurements.
Figure 8. Comparison of total number of sessions per period between 
SA and Web.
Discussion
Patients used the system more intensively when they 
wore the continuous glucose sensor, in terms of number 
of sessions and total time of system use.
During the control phase, the number of SA sessions 
was significantly lower, but patients performed more 
tasks per session. Our interpretation is that patients used 
the SA less frequently, so they concentrate more actions 
per session.
When analyzing patients’ behavior within a SA session, 
we observe that, during the intervention phase, patients 
access more often the graphic representation of data 
and the consultation of insulin therapy and diet. In our 
opinion, one of the reasons is that they have access to 
more information integrated in the SA, and this helps 
them to make their decisions.
Patients’ behavior change is reflected in the use of the 
functionalities of the system, the average number of daily 
insulin boluses, and the number of BG measurements, 
which were higher during the intervention phase 
than in the control phase. The availability of the CGM 
information drove patients to administer extra boluses 
frequently to control the glycemic levels better after 
having confirmed the CGM readings with extra BG 
measurements. For this reason, the percentage of BG 
measurements in times of the day not associated to meals 
was higher during the intervention phase.
The mobility and independence provided by the PDA 
application competes with the higher usability of the 
Web application. Objective results show that patients 
prefer mobility instead of usability, because they used 
the SA more intensively than the Web, even for those 
functionalities that are common to both applications. 
Additionally, patients explicitly stated that the SA helped 
them with their control of diabetes without making their 
daily life harder.
The mobility of the whole system could be incremented 
if BG data could be directly downloaded into the PDA 
instead of using the Acculink modem that requires a 
wired connection. However, the Acculink modem makes 
it possible to download data from anywhere a phone line 
is available, without the need of having a computer, so the 
SA can be an alternative to feedback for the patients 
regarding data transfer, providing them with more 
freedom than computer access. From a technical point of 
view, it is possible to directly download glucose meters to 
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the presented SA using both a data cable or a wireless 
(Bluetooth) connection,21 but this requires a specific 
software development for each commercial device since 
there are no communication standards implemented by 
medical device manufacturers.
There are international initiatives, like Continua Health 
Alliance,25 to get a common standard for medical device 
communication in ambulatory scenarios by extending 
the family of standards International Organization of 
Standardization 11073/IEEE 1073 (X73)26 and encouraging 
manufacturers to adapt their products to the standard. 
To the best of the authors’ knowledge there is only one 
“diabetes product” certified by Continua, Roche Accu-Check®
Smart Pix Device Reader, limited to Roche glucose meters 
and insulin pumps and using the USB interface for data 
transfer. Therefore, a lot of work remains to be done in 
the area of device integration into mobile scenarios for 
diabetes care.
Conclusions
The use of CGM changes the way patients manage their 
diabetes, as observed in the increased number of daily 
insulin bolus, the increased number of daily BG measure- 
ments, and the differences in the distribution of BG 
measurements along the day. Continuous monitoring also 
increases the interaction of patients with the information 
system and modifies their patterns of use.
We can conclude that mobile technologies are especially 
useful in scenarios of tight monitoring in diabetes and 
that they are well accepted by patients, who would 
recommend the use of DIABTel in routine care.
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